Shanghai Fosun Pharmaceutical Group Co Ltd (600196)
Shanghai Stock Exchange · China · prices in CNY · close of 23 Oct 2026
Key indicators
| Last close | CNY 23.18 |
|---|---|
| 52-week range | 20.85 – 29.68 |
| Return, 1 month / 3 months | +0.2% / −0.5% |
| Return, 1 year / 3 years | −19.7% / −13.6% |
| Trend | Below its 200-day average |
| RSI (14) | 52 |
| Volatility (1 year) | 25.9% |
| Worst drawdown (1 year) | -27.7% |
| Average daily value traded | 546.74M CNY |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Shanghai Fosun Pharmaceutical Group develops, makes and distributes medicines and medical products. Its pharmaceutical business covers generic drugs, active ingredients and treatments in areas such as anti-infection, cardiovascular and metabolic disease, and it also provides healthcare services through hospitals and medical institutions. The company supplies hospitals, pharmacies and distributors, mainly in China, and is based in Shanghai as part of the wider Fosun group.
On this site Shanghai Fosun Pharmaceutical Group Co Ltd appears as a stock on the Shanghai Stock Exchange (China), code 600196, with prices in Chinese yuan (CNY). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Shanghai Fosun Pharmaceutical Group Co Ltd (600196) trades on the Shanghai Stock Exchange in China. It last closed at CNY 23.18 on 23 October 2026.
Its price-based Market X-Ray is 73 out of 100 (a strong price profile), ranking 197 of 2,278 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 19.7% and over the last three months it fell 0.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Shanghai Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 74 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | -5.5% | ||
| From 52-week high | -20.6% | ||
| Momentum | 50 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -0.5% | ||
| 6-month return | -9.3% | ||
| 12-month return, skipping the last month | -19.9% | ||
| Stability (higher is calmer) | 89 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 25.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -27.7% | ||
| Liquidity | 84 · Strong | Trades actively. | |
| Average daily value traded | 546.74M CNY | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 2 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +0.9% |
|---|---|
| 1 month | +0.2% |
| 3 months | −0.5% |
| 6 months | −9.3% |
| 1 year | −19.7% |
| 3 years | −13.6% |
| 5 years | −54.1% |
Signals
| 50-day / 200-day average | 23.08 / 24.52 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.54 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 9 Aug 2023 | CNY 0.4200 |
| 16 Jun 2022 | CNY 0.5600 |
| 19 Jul 2021 | CNY 0.4300 |
| 30 Jul 2020 | CNY 0.3900 |
| 2 Aug 2019 | CNY 0.3200 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Shanghai Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.